Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Post by Charly50on Jan 31, 2021 1:47am
328 Views
Post# 32430528

Wer legt den Shorties das Handwerk!

Wer legt den Shorties das Handwerk!Big Pharma: Das Ende der Zurckhaltung! Stammzelltherapien: Diabetes, Herzschwche, Parkinson - Stammzellen sollen alles heilen. Pfizer bernimmt die Fhrung in dem potentiell hchst lukrativem Geschft mit Stammzelltherapien. Der Schweizer Pharmakonzern Roche zahlte Millionen US-Dollar um Zugriff auf deren innovative Stammzell-Technologien zu erhalten. Rangelei um die Pltze ! Die Liste der Firmen liee sich noch beliebig erweitern: Fr Novartis, GlaxoSmithKline und AstraZeneca (Nummer 2, 5 und 7 auf der Liste der grten Pharmaunternehmen) sind hnliche Aktivitten zu verzeichnen. Wie bei Roche geht es anfnglich um den Test von pharmakologischen Substanzen im Labor, doch muss man kein Prophet sein, um dies auch als Einstieg in das Therapiegeschft zu deuten. Die Rangelei um die Pltze am Fleischtopf hat begonnen. Quelle: wissensschau.de
<< Previous
Bullboard Posts
Next >>